TY - JOUR
T1 - Medical abortion in the late first trimester
T2 - a systematic review
AU - Kapp, Nathalie
AU - Eckersberger, Elisabeth
AU - Lavelanet, Antonella
AU - Rodriguez, Maria Isabel
N1 - Funding Information:
We are grateful to Alli Buehler for her assistance developing our search strategies. Funding for this review was supplied by WHO/ RHR. Dr. Rodriguez is a Women's Reproductive Health Research fellow; grant 1K12HD085809.
Publisher Copyright:
© 2018 The Author(s)
PY - 2019/2
Y1 - 2019/2
N2 - Objective: To describe the efficacy, safety, and acceptability of medical abortion in the late first trimester. Study design: We searched PubMed and Cochrane databases for articles in any language that examined the success of medical abortion at gestational ages (>63 to≤84 days gestation). We sought articles that compared: medical abortion with surgical abortion at this gestational age, combination mifepristone and misoprostol and/or misoprostol alone); different dosages of misoprostol; different routes of misoprostol administration; frequency of dosing; and location of medical abortion (in health care facility vs. outpatient management). Our primary outcome was complete abortion. Data was independently abstracted by two authors, graded for evidence quality, and assessed for risk of bias. Results: The search strategy returned 3384 articles, nine of which met inclusion criteria. Medical abortion, as compared with surgical abortion, was effective in the late first trimester (94.6% versus 97.9% complete abortion). A combined regimen of mifepristone and misoprostol was significantly more effective than misoprostol alone (90.4 versus 81.6% complete abortion). Complete abortion rates for all regimens investigated ranged from 78.6% to 94.6%. Success rates were higher with repeat dosing of misoprostol both in combination regimens and alone, and with vaginal compared with oral administration for repeat dosing. Conclusion: A limited body of evidence indicates a range of efficacy of medical abortion in the late first trimester and highlights the need for well-designed trials in this gestational age range. Implications: This review highlights the need for research focused on the late first trimester to strengthen the body of evidence. The available evidence is limited but offers reassurance that adverse events are rare for later first trimester abortion. Importantly, new research demonstrates that efficacy remains unchanged in the 10th gestational week regardless of whether the medication is taken in a facility or at a woman's home.
AB - Objective: To describe the efficacy, safety, and acceptability of medical abortion in the late first trimester. Study design: We searched PubMed and Cochrane databases for articles in any language that examined the success of medical abortion at gestational ages (>63 to≤84 days gestation). We sought articles that compared: medical abortion with surgical abortion at this gestational age, combination mifepristone and misoprostol and/or misoprostol alone); different dosages of misoprostol; different routes of misoprostol administration; frequency of dosing; and location of medical abortion (in health care facility vs. outpatient management). Our primary outcome was complete abortion. Data was independently abstracted by two authors, graded for evidence quality, and assessed for risk of bias. Results: The search strategy returned 3384 articles, nine of which met inclusion criteria. Medical abortion, as compared with surgical abortion, was effective in the late first trimester (94.6% versus 97.9% complete abortion). A combined regimen of mifepristone and misoprostol was significantly more effective than misoprostol alone (90.4 versus 81.6% complete abortion). Complete abortion rates for all regimens investigated ranged from 78.6% to 94.6%. Success rates were higher with repeat dosing of misoprostol both in combination regimens and alone, and with vaginal compared with oral administration for repeat dosing. Conclusion: A limited body of evidence indicates a range of efficacy of medical abortion in the late first trimester and highlights the need for well-designed trials in this gestational age range. Implications: This review highlights the need for research focused on the late first trimester to strengthen the body of evidence. The available evidence is limited but offers reassurance that adverse events are rare for later first trimester abortion. Importantly, new research demonstrates that efficacy remains unchanged in the 10th gestational week regardless of whether the medication is taken in a facility or at a woman's home.
KW - Late medical abortion
KW - Medical abortion efficacy
KW - Mifepristone
KW - Misoprostol
UR - http://www.scopus.com/inward/record.url?scp=85057626181&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057626181&partnerID=8YFLogxK
U2 - 10.1016/j.contraception.2018.11.002
DO - 10.1016/j.contraception.2018.11.002
M3 - Review article
C2 - 30444970
AN - SCOPUS:85057626181
SN - 0010-7824
VL - 99
SP - 77
EP - 86
JO - Contraception
JF - Contraception
IS - 2
ER -